|
業務類別
|
Biotechnology |
|
業務概覽
|
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. |
| 公司地址
| Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004 |
| 電話號碼
| +1 844 511-9056 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.larimartx.com |
| 員工數量
| 65 |
| Mr. Michael Celano |
Chief Financial Officer, Secretary and Principal Accounting Officer |
美元 441.93K |
11/04/2025 |
| Dr. Carole Ben-Maimon, M.D. |
Director, President and Chief Executive Officer |
美元 600.00K |
11/04/2025 |
| Dr. Gopi Shankar, F.A.A.P.,M.B.A.,PhD |
Chief Development Officer |
美元 440.58K |
11/04/2025 |
| Dr. Russell G. Clayton, D.O. |
Chief Medical Officer |
-- |
11/04/2025 |
|
|
| Mr. Frank E. Thomas |
Independent Director |
11/04/2025 |
| Mr. Jonathan S. Leff |
Independent Director |
11/04/2025 |
| Mr. Joseph Truitt |
Chairman of the Board |
11/04/2025 |
| Dr. Carole Ben-Maimon, M.D. |
Director, President and Chief Executive Officer |
11/04/2025 |
| Mr. Thomas Edward Hamilton |
Independent Director |
11/04/2025 |
| Dr. Jeffrey W. Sherman, F.A.C.P.,M.D. |
Independent Director |
11/04/2025 |
|
|
|
|
